Kornimate/medical-research-clean huggingface dataset:
neurophysiological validation of the clinical criteria of sensitization in chronic pelvic and perineal pain population

Conditions: Chronic Pelvic Pain; Chronic Perineal Pain

Summary: the purpose of this study is to assess and validate the clinical criteria of sensitization ("convergences pp criteria") selected by the expert consensus with neurophysiological sensory testing.

some patient with chronic pelvic or perineal pain, present complex manifestations, comprising pain and dysfunction which does not involved a single organ. the gap between clinical symptoms and pathological signs is a constant feature of these pain syndromes. a possible explanation for these pain syndromes is central sensitization. this sensitization is defined by decrease nociceptive thresholds, a more intense and more prolonged response to nociceptive stimulus, and spatial extension of the painful area. it has been defined by international expert consensus in 2016 a clinical evaluation tool with 10 criteria for sensitization diagnosis: convergences pp criteria. the aim of this study is to objectivize lower threshold, spatial and temporal diffusion of pain in women with chronic pelvic or perineal pain with sensitization (convergences pp criteria \> 5) compared to women without sensitization (convergences pp criteria \< 5). a sensory testing of lower urinary tract, lower rectal tract, vulva and pelvic muscles will be achieved.

Eligibility criteria:
inclusion criteria: * women \> 25 years, * pelvic or perineal pain since \> 3 months, * no injury in pelvic imagery or clinical examination that may explain all the pain complaint, * patient who can understand the protocol, * patient who agreed and signed the informed consent for participation. exclusion criteria: * poor understanding of french language, * pregnancy or lactation, * severe depression (beck depression inventory-short form \> 16), * initial pain estimation at 10 on numeric analog scale, * inadequately cooperating, * isolated dysmenorrhea, * deep endometriosis with rectal or bladder lesion, * genital or bladder infection, * urogenital tumor history, * anorectal surgery history a type of digestive resection, * anal stenosis, * advanced vaginal prolapse (stage 2 on pop-q scale), * post-traumatic stress disorder history, * deprived of liberty (trusteeship, guardianship).

Keywords: sensitization pain thresholds
diagnosis and survival prediction of pancreatic cancer by machine learning of image data

Conditions: Pancreatic Cancer

Summary: this prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.

in this study, investigators aimed to investigate the diagnostic performance and prediction accuracy of pancreatic cancer by radiomics data and clinical data, which include ct scan, mri, pet-ct, pet-mr, ultrasound, and clinical data.

Eligibility criteria:
inclusion criteria: clinical diagnosis of pancreatic tumor; must have ct / mri / ultrasound data and pathology diagnosis exclusion criteria: have other tumors along with pancreatic tumor; clinical information missing

Keywords: pancreatic cancer machine learning radiomics ct mri ultrasound
incentives to promote sustained linkage to hiv care

Conditions: Human Immunodeficiency Virus; HIV/AIDS

Summary: this study aims to test if small incentives promote linkage to care and 6-month viral suppression among individuals recently tested for hiv at selected sites within johannesburg, south africa. individuals who obtain a reactive hiv test result will be randomized to receive either the standard of care (soc) for linkage to care or to receive financial incentives for confirmatory testing, linkage to care and viral suppression.

this study is in collaboration with ezintsha, a sub-division of wits reproductive health and hiv institute (wrhi) in south africa. this study will leverage on the existing research infrastructure of ezintsha, including, hivss testing through the star initiative (self-test africa), as well as hiv positive persons identified through other ezintsha research studies and at eztinsha affiliated health clinics. this study will use a randomized trial design to test the effectiveness of incentives to increase confirmatory testing, linkage to care and viral suppression. the aim of this study is to determine whether hiv-infected men and women are more likely to achieve or maintain hiv virologic suppression if offered financial incentives vs. no incentives (standard of care). individuals who report receiving a reactive hivss test result on the star programme, or a hiv reactive test in another research study or at a affiliated clinic, will be randomized into one of two groups: a) a control group that receives the standard of care (soc) for linkage to care; and b) an intervention group that receives financial incentives for confirmatory testing, linkage to care, and viral suppression.

Eligibility criteria:
inclusion criteria: * reported hiv positive * have a personal and/or valid phone number, that will remain active for 6 months * have a phone with whatsapp, or text message feature * understand the informed consent form exclusion criteria: * unwilling to provide informed consent * any condition which would make the participant unsuitable or unsafe for enrollment, i.e. being unable to see or read by forgetting to bring reading glasses, being intoxicated or acute sickness

Keywords: hiv self-testing behavioral sciences financial incentives viral suppression
lower urinary tract symptoms

Conditions: Lower Urinary Tract Symptoms

Summary: lower urinary tract symptoms (luts) are observed in individuals with pathologies affecting the lower urinary system, such as detrusor overactivity, sphincter weakness, or sensory bladder disorder. luts can be categorized into storage, voiding, and post-micturition symptoms. storage problems include increased frequency of urination, nocturia, urinary urgency, and incontinence. voiding symptoms include decreased urine flow rate, hesitancy, and terminal dribbling, while post-micturition symptoms include post-micturition dribble and a sensation of incomplete bladder emptying. the prevalence of luts increases with age and is influenced by factors such as metabolic syndrome, gender, caffeine consumption habits, chronic psychological stress, bladder dysfunction, smoking, alcohol use, and constipation. this study aims to investigate the prevalence of luts and contributing factors among medical students, a young population undergoing a stressful educational process. a 43-question survey was prepared for all medical students from years 1 to 6. the survey included the constipation scoring system (css) to evaluate constipation, the generalized anxiety disorder-7 (gad-7) score to assess anxiety levels, and the core lower urinary tract symptom score (clss) to query luts. the survey also collected data on participants' dietary habits, smoking, alcohol and caffeine consumption, living conditions, age, gender, body mass index (bmi), and educational level. the study was approved by the local ethics committee of gaziantep university (approval number 2024/234).


Eligibility criteria:
inclusion criteria: -all medical students from committee 1 to 6. exclusion criteria: * participants who filled out the survey questions incompletely or incorrectly * participants who had additional diseases * participants who used medication for psychiatric or cardiac reasons * participants who had undergone surgery that could affect bladder function

Keywords: lower urinary tract symptoms medical students prevalence
long duration holter ecg in fabry disease

Conditions: Fabry Disease

Summary: the main objective is to assess the occurrence of cardiac arrhythmias and conduction disorders during a three-year follow-up using implantable holter ecg monitoring in 40 patients with fabry disease. the secondary objectives are to analyze the correlations of these anomalies with changes in cardiac mri and echocardiographic parameters as biological parameters and overall severity of the disease assessed by mssi.

the main objective of this non-blinded, monocentric non-randomized study is to assess the occurrence of cardiac arrhythmias and conduction disorders (sinus dysfunction, branch block \[bb\], atrioventricular block \[bav\], sustained \[tvs\] or non-supported \[tvns\] ventricular tachycardias, atrial fibrillation \[af\] during a three-year follow-up in 40 patients with fabry disease (half with left ventricular hypertrophy) using an implantable holter ecg device (medtronic reveal-linq™). the secondary objectives are to analyze the correlations (at 1, 2 and 3 years) of these anomalies with the modifications of : * cardiac mri \[magnetic resonance imaging\] data at inclusion \[m0\] and at 36 months \[m36\] (left ventricular hypertrophy \[hvg\], amplitude of the t1 signal, extent of fibrosis); mris will be performed before implantation and after removal of the holter to avoid the reading artifacts linked to the device. * echocardiographic measurements of the left ventricle (overall longitudinal strain systolic \[sgl\] and ejection fraction \[fe\]) * biological parameters (bnp or nt-probnp, ultra-sensitive troponin and lyso-gb3) * the overall severity of the disease assessed by mssi (mainz severity score index), dfg and proteinuria

Eligibility criteria:
inclusion criteria: * male patient * age greater than or equal to 18 years on the day of inclusion * presence of a morbid mutation for mf * signature of the informed consent form * absence of significant valve disease, verified on medical file (absence stenosis or regurgitation \<2+ in color doppler on a scale 1 to 4+ by extension of the jet) * no history of known or documented myocardial infarction nor cad * no pacemaker or icd * no history of af, nsvt, high-degree av block * correct echogenicity * no treatment by corticosteroid or immunosuppressive drugs * creatinine clearance \>/= 30 ml/mn * lvef ≥ 50% by ultrasound and / or mri * no contraindication to mri (or claustrophobia) and gadolinium injection * affiliation to the french social security insurance
an open label study to investigate the pharmacokinetics and pharmacodynamics of repeat escalating doses of the oral akt inhibitor gsk2141795 by 18f fdg pet analysis in subjects with ovarian cancer

Conditions: Solid Tumours

Summary: the purpose of this study is to explore the potential dose response relationship between the pharmacokinetics of gsk2141795 and \[18f\] fdg pet pharmacodynamic markers of glucose metabolism in tumor tissue. three to six subjects will be enrolled in each cohort and dosed with repeat escalating doses of gsk2141795. \[18f\] fdg pet imaging and optional tumor biopsies will be done prior to initiation of dosing and sequentially at select time points during the first five weeks of dosing. the maximal dose of a given schedule evaluated in this study will not exceed the maximal tolerated dose established in the first-time-in-human trial pcs112689 for the same schedule.


Eligibility criteria:
inclusion criteria: 1. capable of giving written informed consent 2. females of non-childbearing potential, 18 years or older with ovarian cancer 3. histologically or cytologically confirmed diagnosis of pet-positive recurrent or persistent ovarian cancer 4. histologically or cytologically confirmed diagnosis of pet-positive recurrent or persistent uterine or gastro-oesophageal tumors (these tumor types will only be included if there is poor enrollment of patients with ovarian cancer) 5. disease at least 2 cm suitable for assessment by imaging 6. performance status score of 0, 1 or 2 according to the eastern cooperative oncology group scale 7. adequate organ systems function exclusion criteria: 1. chemotherapy, radiotherapy, or immunotherapy within 28 days prior to the first dose of gsk2141795 2. use of an investigational anti-cancer drug within 28 days or five half-lives, whichever is shorter, prior to the first dose of gsk2141795 3. current use of a prohibited medication 4. anticoagulants at therapeutic doses are permitted only after consultation with the gsk medical monitor 5. presence of active gastrointestinal disease or other condition that could affect gastrointestinal absorption 6. any major surgery within the last four weeks of screening 7. unresolved toxicity greater than or equal to grade 2 from previous anti-cancer therapy 8. previously diagnosed diabetes mellitus 9. current use of oral corticosteroids, with the exception of inhaled or topical corticosteroids 10. any serious or unstable pre-existing medical, psychiatric, or other condition 11. symptomatic or untreated cns metastases or leptomeningeal involvement 12. evidence of severe or uncontrolled systemic diseases 13. qtc interval ≥ 470 msecs 14. other clinically significant ecg abnormalities 15. history of myocardial infarction, acute coronary syndromes 16. class iii or iv heart failure 17. pregnant or lactating patients 18. history of hepatitis b or c or hiv

Keywords: cancer 18f fdg pk pet positron emission tomography pd akt inhibitor gsk2141795
anxiolytic effectiveness of virtual reality glasses in surgery

Conditions: Anesthesia; Anxiety; Postoperative Pain; Postoperative Recovery

Summary: regional anesthesia allows surgery without affecting the patient's level of consciousness.however, this may cause anxiety in some patients.in previous research, scientists have tried to prevent anxiety with non-pharmacological interventions such as music and cognitive therapies.virtual reality is thought to offer an immersive experience that can alter the mind's perception of pain. scientists have found in previous preliminary studies that virtual reality is safe and effective as an adjunct to standard sedative/analgesic protocols for reducing patients' pain and anxiety during endoscopy, colonoscopy, dental treatments, burn dressings, and labor. in this study, it is expected that anxiety scores, postoperative analgesic need and intraoperative sedation need will decrease, recovery quality will improve and patient satisfaction will increase in patients who will undergo upper extremity surgery under regional anesthesia and watch videos through vr glasses.


Eligibility criteria:
inclusion criteria: * who will undergo upper extremity surgery under regional anesthesia exclusion criteria: * being under 18 years old * those who do not have the ability to read, understand and sign the consent form * an active infection or open wound in the face or eye area * history of seizures due to an epileptic condition or any other reason * planning to wear a hearing aid during the surgical procedure * having a pacemaker or other implanted medical device * migraine * having an infectious condition that is transmitted through droplets or airborne * not knowing turkish * not deemed suitable for the approach by the surgeon * history of psychosis or claustrophobia * being visually and/or hearing impaired
pattern recognition and anomaly detection in fetal morphology using deep learning and statistical learning

Conditions: Congenital Abnormalities

Summary: congenital anomalies (ca) are the most encountered cause of fetal death, infant mortality and morbidity.7.9 million infants are born with ca yearly. early detection of ca facilitates life-saving treatments and stops the progression of disabilities. ca can be diagnosed prenatally through morphology scan (ms). discrepancies between pre and postnatal diagnosis of ca reach 29%. a correct interpretation of ms allows a detailed discussion regarding the prognosis with parents. the central feature of paradise is the development of a specialized intelligent system that embeds a committee of deep learning and statistical learning methods, which work together in a competitive/collaborative way to increase the performance of ms examinations by signaling ca. using preclinical testing and clinical validation, the main goal will be the direct implementation into clinical practice. this multi-disciplinary project offers a unique integration of approaches, competences, breakthroughs in key applications in human, psychological, technological, and economical interest such as the 'smarter' healthcare system, opening new fields of research. paradise creates an environment that contributes significantly to the healthcare system, medical and pharma industries, scientific community, economy and ultimately to each individual. its outcome will increase impact on the management of ca by enabling the establishment of detailed plans before birth, which will decrease morbidity and mortality in infants.

probe guidance: the is guides the sonographer's probe for better acquisition of the fetal biometric plane - basic scanning to be performed by non-expert(\> 90% accuracy (ac)) fetal biometric plane finder: the fetal planes are automatically detected, measured and stored - insurance that all anatomical parts are checked (100% ac) anomaly detection: unusual findings are signaled - assistance in decision making (\>90% ac)

Eligibility criteria:
inclusion criteria: * second trimester pregnant women exclusion criteria: -

Keywords: ultrasound fetal morphology view planes deep learning learning curves
study of intraperitoneal carboplatin with iv paclitaxel and bevacizumab in untreated ovarian cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; No Prior Chemotherapy

Summary: phase i study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma.

phase i study with the primary objective to determine the maximum tolerated dose of intraperitoneal carboplatin and intravenous weekly paclitaxel given in combination with intravenous bevacizumab during the second two cycles of treatment in patients with chemo-naive epithelial ovarian, primary peritoneal or fallopian tube cancer. the maximum tolerated dose is defined as the highest dose at which no more than 1 of 6 evaluable patients experiences a dose limiting toxicity during the second two cycles of treatment. secondary objectives are to determine response rates and to estimate progression free survival and overall survival of this class of patients.

Eligibility criteria:
inclusion criteria: * histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(stage ii, iii or iv)either optimal or suboptimal after initial surgery. * all patients must have had appropriate surgery for ovarian, peritoneal, or fallopian tube carcinoma with tissue available for histologic evaluation * histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant brenner tumor, adenocarcinoma nos. * gog(gynecologic oncology group)performance status of 0,1,2 * entered within 12 weeks of most recent surgery performed for diagnosis. * patients must have adequate bone marrow function, renal function,hepatic function, neurologic function, blood coagulation parameters within normal limits * sign approved consent form. exclusion criteria: * patients who have received prior treatment other than initial surgery * patients who have received prior radiotherapy to any portion of their abdominal cavity or pelvis * patients with acute hepatitis or active infection * patients with active bleeding * patients with unstable angina * patients with history of invasive malignancies with the exception of nonmelanoma skin cancer and localized breast cancer. * patients who have received any target therapy or hormonal therapy for management of their ovarian cancer. * patients with synchronous primary endometrial cancer. * patients with epithelial tumors of low malignant potential * serious non healing wound, ulcer or bone fracture. * patients with history or evidence of cns(central nervous system disease) * patients under 18 years old. * patients who have received prior therapy with anti-vegf(vascular endothelial growth factor) drug, bevacizumab * patients who have a history of allergic reaction to polysorbate 80.

Keywords: ovarian cancer fallopian tube peritoneal intraperitoneal bevacizumab carboplatin paclitaxel chemo-naive
catastrophism among chronic pain patients in rheumatology

Conditions: Catastrophizing Pain

Summary: pain catastrophizing is conceptualized as a negative cognitive-affective response to anticipated or actual pain and has been associated with a number of important pain-related outcomes. the aims of this study are 1. to describe the characteristics of the patients and determinants of catastrophizing in chronic painful patients hospitalized in rheumatology in the nîmes university hospital 2. to describe the impact of the catastrophizing on the level of insomnia and the drugs consumption in chronic painful patients hospitalized in rheumatology in the nîmes university hospital


Eligibility criteria:
inclusion criteria: * adults hospitalized in the department of rheumatology of the nîmes university hospital with chronic pain (≥ 6 months) exclusion criteria: * benzodiazepine or neuroleptic use for epilepsia, alcool, psychiatric disorders * restless legs syndrom * obstructive sleep apnea * narcolepsy
airway clearance by fiberoptic bronchoscopy in bronchiectasis followed by gentamicin and dexamethason injection

Conditions: Bronchiectasis Adult; Bronchiectasis With Acute Exacerbation

Summary: fiberoptic bronchoscopic removal of secretions and antibiotic injection

fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance

Eligibility criteria:
inclusion criteria: 1- adult subjects. 2- male and female subjects are enrolled. 3- patients with ncfb confirmed by chest high-resolution computed tomography (hrct) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- patients who underwent ac by bronchoscopy at the hospital. - exclusion criteria: 1- uncooperative subjects. 2- unwilling to participate. 3- inability to lie on the back with raised arms over the head for hrct. 4- presence of cystic pulmonary fibrosis; 5- patients with active pulmonary tuberculosis; 6- those awaiting surgery; 7- patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (abpa); 8- patients who did not undergo bronchoscopy for different reasons or combined with lung cancer. -

Keywords: bronchoscopy bronchiectasis